Neuberger Berman Group
NBIX icon

Neuberger Berman Group’s Neurocrine Biosciences NBIX Stock Holding History

Neuberger Berman Group’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.52M Buy
11,535
+376
+3% +$49.9K ﹤0.01% 1272
2025
Q4 		$1.58M Buy
11,159
+606
+6% +$87.8K ﹤0.01% 1258
2025
Q3 		$1.48M Sell
10,553
-12
-0.1% -$1.63K ﹤0.01% 1241
2025
Q2 		$1.33M Buy
10,565
+1,857
+21% +$213K ﹤0.01% 1257
2025
Q1 		$963K Sell
8,708
-159,468
-95% -$20.2M ﹤0.01% 1327
2024
Q4 		$23M Buy
168,176
+8,633
+5% +$1.07M 0.02% 623
2024
Q3 		$18.4M Buy
159,543
+35,802
+29% +$4.91M 0.01% 678
2024
Q2 		$17M Buy
123,741
+6,709
+6% +$920K 0.01% 669
2024
Q1 		$16.1M Buy
117,032
+3,275
+3% +$447K 0.01% 696
2023
Q4 		$15M Buy
113,757
+3,012
+3% +$347K 0.01% 687
2023
Q3 		$12.5M Buy
110,745
+355
+0.3% +$37.4K 0.01% 703
2023
Q2 		$10.4M Buy
110,390
+103,961
+1,617% +$10.2M 0.01% 739
2023
Q1 		$651K Sell
6,429
-33
-0.5% -$3.43K ﹤0.01% 1377
2022
Q4 		$772K Sell
6,462
-86
-1% -$10.1K ﹤0.01% 1316
2022
Q3 		$696K Sell
6,548
-1,141
-15% -$116K ﹤0.01% 1368
2022
Q2 		$750K Buy
7,689
+207
+3% +$19.1K ﹤0.01% 1368
2022
Q1 		$702K Buy
7,482
+2,948
+65% +$250K ﹤0.01% 1445
2021
Q4 		$379K Buy
4,534
+1,365
+43% +$126K ﹤0.01% 1632
2021
Q3 		$301K Buy
3,169
+28
+0.9% +$2.65K ﹤0.01% 1602
2021
Q2 		$305K Buy
3,141
+191
+6% +$18.3K ﹤0.01% 1606
2021
Q1 		$287K Sell
2,950
-330
-10% -$34.6K ﹤0.01% 1621
2020
Q4 		$315K Buy
3,280
+19
+0.6% +$1.83K ﹤0.01% 1507
2020
Q3 		$314K Buy
3,261
+330
+11% +$38.2K ﹤0.01% 1443
2020
Q2 		$358K Sell
2,931
-51,832
-95% -$5.73M ﹤0.01% 1341
2020
Q1 		$4.74M Sell
54,763
-5,827
-10% -$570K 0.01% 796
2019
Q4 		$6.51M Sell
60,590
-2,135
-3% -$224K 0.01% 814
2019
Q3 		$5.65M Buy
+62,725
New +$5.86M 0.01% 825
2019
Q2 		– Sell
-80,284
Closed -$7.07M – 1578
2019
Q1 		$7.07M Sell
80,284
-77,663
-49% -$6.49M 0.01% 794
2018
Q4 		$11.3M Sell
157,947
-126,635
-44% -$12.1M 0.02% 717
2018
Q3 		$35M Sell
284,582
-46,913
-14% -$5.32M 0.04% 489
2018
Q2 		$32.6M Sell
331,495
-29,300
-8% -$2.62M 0.04% 514
2018
Q1 		$29.9M Sell
360,795
-116,000
-24% -$9.8M 0.03% 532
2017
Q4 		$37M Buy
476,795
+21,500
+5% +$1.47M 0.04% 482
2017
Q3 		$27.9M Sell
455,295
-9,309
-2% -$491K 0.03% 532
2017
Q2 		$21.4M Buy
464,604
+33,021
+8% +$1.6M 0.03% 594
2017
Q1 		$18.7M Buy
431,583
+112,500
+35% +$4.82M 0.02% 616
2016
Q4 		$12.3M Buy
319,083
+302,704
+1,848% +$13.7M 0.02% 707
2016
Q3 		$829K Buy
+16,379
New +$816K ﹤0.01% 1150
2016
Q2 		– Sell
-10,352
Closed -$409K – 1569
2016
Q1 		$409K Sell
10,352
-16,135
-61% -$640K ﹤0.01% 1307
2015
Q4 		$1.5M Buy
+26,487
New +$1.35M ﹤0.01% 1054

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Neuberger Berman Group's NBIX Position: Q1 2026 in Review

Neuberger Berman Group increased its Neurocrine Biosciences (NBIX) stake by 3.4% in Q1 2026, buying an estimated $49.9K and bringing the position to 11,535 shares worth $1.52M. The position accounts for ﹤0.01% of the portfolio, ranked #1272.

Neuberger Berman Group first reported a position in NBIX in Q4 2015 and has held it in 40 quarters since. The position peaked at $37M in Q4 2017. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Neuberger Berman Group held 11,535 shares of Neurocrine Biosciences worth $1.52M as of Q1 2026.
  • Neuberger Berman Group bought 376 Neurocrine Biosciences shares in Q1 2026, an estimated $49.9K.
  • Neurocrine Biosciences made up ﹤0.01% of Neuberger Berman Group's portfolio in Q1 2026, its #1272 holding.
  • Neuberger Berman Group first reported a position in Neurocrine Biosciences in Q4 2015 and has held it in 40 quarters since.
  • Neuberger Berman Group's Neurocrine Biosciences position peaked at $37M in Q4 2017.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.